Eptifibatide overdose

Sagun Parakh, Nimesh Naik, Nidhi Rohatgi, Utsav Bhat, Kapil Parakh

Research output: Contribution to journalArticle

Abstract

Background: Eptifibatide is a glycoprotein (GP) IIb/IIIa inhibitor used globally, but there is little information on overdose. We report a case of eptifibatide overdose with no consequence to the patient. Methods: We searched for eptifibatide overdose on PubMed, British National Formulary, Thomson Micromedex, EudraPharm, Toxbase, and the Medicines and Healthcare products Regulatory Agency and Food and Drug Administration websites. Results: In clinical trials, overdose occurred in 17 cases with no adverse events including bleeding. In case reports, prolonged infusions of eptifibatide were associated with gastrointestinal bleeding and thrombocytopenia. In animal studies, eptifibatide was not lethal but induced dyspnea, ptosis, cerebellar dysfunction, hypotonia and petechial hemorrhages. Eptifibatide side effects including chest pain, bradycardia, angioedema and hypotension may occur in patients with overdose. Alveolar hemorrhage should be suspected in patients with hemoptysis, dyspnea or new infiltrates on chest X-ray. Management of overdose requires discontinuation of eptifibatide, monitoring for bleeding and waiting for clearance (primarily renal). Normalization of hemostasis occurs rapidly and coronary bypass surgery performed within 2 hours of eptifibatide discontinuation did not have excess bleeding. Eptifibatide clearance is delayed in renal failure and in one report hemodialysis normalized hemostasis. Platelet transfusion is appropriate in cases of acute thrombocytopenia, a side effect of eptifibatide. If the platelet count is normal, transfusion of platelets does not help as drug molecules overwhelmingly outnumber GP IIb/IIIa receptors. Desmopressin reversed platelet dysfunction caused by eptifibatide in healthy volunteers but is untested in patients. Conclusion: Available data suggest that eptifibatide overdose is rare and can be managed conservatively.

Original languageEnglish (US)
Pages (from-to)430-432
Number of pages3
JournalInternational Journal of Cardiology
Volume131
Issue number3
DOIs
StatePublished - Jan 24 2009

Fingerprint

Hemorrhage
Platelet Transfusion
Platelet Glycoprotein GPIIb-IIIa Complex
Hemostasis
Thrombocytopenia
Dyspnea
eptifibatide
Cerebellar Diseases
Deamino Arginine Vasopressin
Angioedema
Pharmacopoeias
Muscle Hypotonia
Hemoptysis
United States Food and Drug Administration
Bradycardia
Chest Pain
Platelet Count
PubMed
Hypotension
Renal Insufficiency

Keywords

  • Acute coronary syndrome
  • Eptifibatide
  • Overdose

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Parakh, S., Naik, N., Rohatgi, N., Bhat, U., & Parakh, K. (2009). Eptifibatide overdose. International Journal of Cardiology, 131(3), 430-432. https://doi.org/10.1016/j.ijcard.2007.07.132

Eptifibatide overdose. / Parakh, Sagun; Naik, Nimesh; Rohatgi, Nidhi; Bhat, Utsav; Parakh, Kapil.

In: International Journal of Cardiology, Vol. 131, No. 3, 24.01.2009, p. 430-432.

Research output: Contribution to journalArticle

Parakh, S, Naik, N, Rohatgi, N, Bhat, U & Parakh, K 2009, 'Eptifibatide overdose', International Journal of Cardiology, vol. 131, no. 3, pp. 430-432. https://doi.org/10.1016/j.ijcard.2007.07.132
Parakh S, Naik N, Rohatgi N, Bhat U, Parakh K. Eptifibatide overdose. International Journal of Cardiology. 2009 Jan 24;131(3):430-432. https://doi.org/10.1016/j.ijcard.2007.07.132
Parakh, Sagun ; Naik, Nimesh ; Rohatgi, Nidhi ; Bhat, Utsav ; Parakh, Kapil. / Eptifibatide overdose. In: International Journal of Cardiology. 2009 ; Vol. 131, No. 3. pp. 430-432.
@article{c6044896b30a4f7e9845f883f44d83dc,
title = "Eptifibatide overdose",
abstract = "Background: Eptifibatide is a glycoprotein (GP) IIb/IIIa inhibitor used globally, but there is little information on overdose. We report a case of eptifibatide overdose with no consequence to the patient. Methods: We searched for eptifibatide overdose on PubMed, British National Formulary, Thomson Micromedex, EudraPharm, Toxbase, and the Medicines and Healthcare products Regulatory Agency and Food and Drug Administration websites. Results: In clinical trials, overdose occurred in 17 cases with no adverse events including bleeding. In case reports, prolonged infusions of eptifibatide were associated with gastrointestinal bleeding and thrombocytopenia. In animal studies, eptifibatide was not lethal but induced dyspnea, ptosis, cerebellar dysfunction, hypotonia and petechial hemorrhages. Eptifibatide side effects including chest pain, bradycardia, angioedema and hypotension may occur in patients with overdose. Alveolar hemorrhage should be suspected in patients with hemoptysis, dyspnea or new infiltrates on chest X-ray. Management of overdose requires discontinuation of eptifibatide, monitoring for bleeding and waiting for clearance (primarily renal). Normalization of hemostasis occurs rapidly and coronary bypass surgery performed within 2 hours of eptifibatide discontinuation did not have excess bleeding. Eptifibatide clearance is delayed in renal failure and in one report hemodialysis normalized hemostasis. Platelet transfusion is appropriate in cases of acute thrombocytopenia, a side effect of eptifibatide. If the platelet count is normal, transfusion of platelets does not help as drug molecules overwhelmingly outnumber GP IIb/IIIa receptors. Desmopressin reversed platelet dysfunction caused by eptifibatide in healthy volunteers but is untested in patients. Conclusion: Available data suggest that eptifibatide overdose is rare and can be managed conservatively.",
keywords = "Acute coronary syndrome, Eptifibatide, Overdose",
author = "Sagun Parakh and Nimesh Naik and Nidhi Rohatgi and Utsav Bhat and Kapil Parakh",
year = "2009",
month = "1",
day = "24",
doi = "10.1016/j.ijcard.2007.07.132",
language = "English (US)",
volume = "131",
pages = "430--432",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Eptifibatide overdose

AU - Parakh, Sagun

AU - Naik, Nimesh

AU - Rohatgi, Nidhi

AU - Bhat, Utsav

AU - Parakh, Kapil

PY - 2009/1/24

Y1 - 2009/1/24

N2 - Background: Eptifibatide is a glycoprotein (GP) IIb/IIIa inhibitor used globally, but there is little information on overdose. We report a case of eptifibatide overdose with no consequence to the patient. Methods: We searched for eptifibatide overdose on PubMed, British National Formulary, Thomson Micromedex, EudraPharm, Toxbase, and the Medicines and Healthcare products Regulatory Agency and Food and Drug Administration websites. Results: In clinical trials, overdose occurred in 17 cases with no adverse events including bleeding. In case reports, prolonged infusions of eptifibatide were associated with gastrointestinal bleeding and thrombocytopenia. In animal studies, eptifibatide was not lethal but induced dyspnea, ptosis, cerebellar dysfunction, hypotonia and petechial hemorrhages. Eptifibatide side effects including chest pain, bradycardia, angioedema and hypotension may occur in patients with overdose. Alveolar hemorrhage should be suspected in patients with hemoptysis, dyspnea or new infiltrates on chest X-ray. Management of overdose requires discontinuation of eptifibatide, monitoring for bleeding and waiting for clearance (primarily renal). Normalization of hemostasis occurs rapidly and coronary bypass surgery performed within 2 hours of eptifibatide discontinuation did not have excess bleeding. Eptifibatide clearance is delayed in renal failure and in one report hemodialysis normalized hemostasis. Platelet transfusion is appropriate in cases of acute thrombocytopenia, a side effect of eptifibatide. If the platelet count is normal, transfusion of platelets does not help as drug molecules overwhelmingly outnumber GP IIb/IIIa receptors. Desmopressin reversed platelet dysfunction caused by eptifibatide in healthy volunteers but is untested in patients. Conclusion: Available data suggest that eptifibatide overdose is rare and can be managed conservatively.

AB - Background: Eptifibatide is a glycoprotein (GP) IIb/IIIa inhibitor used globally, but there is little information on overdose. We report a case of eptifibatide overdose with no consequence to the patient. Methods: We searched for eptifibatide overdose on PubMed, British National Formulary, Thomson Micromedex, EudraPharm, Toxbase, and the Medicines and Healthcare products Regulatory Agency and Food and Drug Administration websites. Results: In clinical trials, overdose occurred in 17 cases with no adverse events including bleeding. In case reports, prolonged infusions of eptifibatide were associated with gastrointestinal bleeding and thrombocytopenia. In animal studies, eptifibatide was not lethal but induced dyspnea, ptosis, cerebellar dysfunction, hypotonia and petechial hemorrhages. Eptifibatide side effects including chest pain, bradycardia, angioedema and hypotension may occur in patients with overdose. Alveolar hemorrhage should be suspected in patients with hemoptysis, dyspnea or new infiltrates on chest X-ray. Management of overdose requires discontinuation of eptifibatide, monitoring for bleeding and waiting for clearance (primarily renal). Normalization of hemostasis occurs rapidly and coronary bypass surgery performed within 2 hours of eptifibatide discontinuation did not have excess bleeding. Eptifibatide clearance is delayed in renal failure and in one report hemodialysis normalized hemostasis. Platelet transfusion is appropriate in cases of acute thrombocytopenia, a side effect of eptifibatide. If the platelet count is normal, transfusion of platelets does not help as drug molecules overwhelmingly outnumber GP IIb/IIIa receptors. Desmopressin reversed platelet dysfunction caused by eptifibatide in healthy volunteers but is untested in patients. Conclusion: Available data suggest that eptifibatide overdose is rare and can be managed conservatively.

KW - Acute coronary syndrome

KW - Eptifibatide

KW - Overdose

UR - http://www.scopus.com/inward/record.url?scp=58149186603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149186603&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2007.07.132

DO - 10.1016/j.ijcard.2007.07.132

M3 - Article

VL - 131

SP - 430

EP - 432

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -